Hodgkin Disease
Conditions
Keywords
Hodgkin Lymphoma, Lenalidomide, Anti-neoplastic agents, Thalidomide
Brief summary
The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
Detailed description
Hodgkin lymphoma (HL), an uncommon but significant subtype of lymphoma, is divided into classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL). Progress has been made in cHL therapy resulting in 5-year failure free survival rates between 61%-89% even in the setting of advanced stage or bulky disease. Patients who relapse however, have a variable prognosis ranging from a 8-year overall survival rate of less than 8% for patients who never achieve a remission to 54% for patients with a complete remission lasting greater than 12 months. High dose chemotherapy with autologous stem cell support is the standard of care for patients with relapsed cHL but for those that relapse despite aggressive salvage therapy 20 - 50%, with median remission durations of approximately 6 months. Furthermore, a subset of relapsed HL patients may not be candidates for aggressive salvage regimens. These novel salvage therapies are needed for relapsed/refractory cHL, especially agents without serious late toxicities are particularly attractive in this disease. Advances in the understanding of HL pathogenesis and lenalidomide's mechanisms of action provide substantial rationale for evaluating lenalidomide in HL patients.
Interventions
DRUGLenalidomide
Sponsors
Celgene Corporation
Washington University School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically documented classical Hodgkin lymphoma that is recurrent or refractory to standard chemotherapy. * Patients must have relapsed or progressed after at least one prior systemic cytotoxic chemotherapy; prior autologous or allogeneic stem cell transplantation is allowed. * Measurable disease must be present either on physical examination or imaging studies (CT, MRI, PET/CT). Any tumor mass greater or equal to 1 cm is acceptable. * Age \> 18 years old. * ECOG performance status of less than or equal to 2 at study entry * Adequate hematologic, renal, hepatic function as defined by: * Absolute neutrophil count greater than or equal to 1000 / uL * Platelets greater than or equal to 50,000 / uL * Serum creatinine less than or equal to 1.5X institution upper limit of normal (ULN) * Total bilirubin less than or equal to 2.0 mg/dL * AST (SGOT) and ALT (SGPT) less than or equal to 3 x ULN (if not attributed to cHL) * Disease free of prior malignancies for greater than or equal to 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast. * Understand and voluntarily sign an informed consent form. * Able to adhere to the study visit schedule and other protocol requirements * Females of childbearing potential (FCBP)† must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal \[birth control pills, injections, or implants\], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed. * FCBP must have two negative serum or urine pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by RevAssist) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative. * Men must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy. * All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. * Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight * All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist.
Exclusion criteria
* Patients who are candidates for high dose chemotherapy and stem cell transplantation and have not yet undergone stem cell transplantation should not be enrolled. * Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. * Any condition, including the presence of laboratory abnormalities. * Use of any other anti-cancer drug or therapy, including experimental, within 30 days of enrollment. * Known hypersensitivity to thalidomide. * The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. * Any prior use of lenalidomide. * Known positive for HIV or infectious hepatitis, type A, B or C. * Pregnant or breastfeeding females. * Concurrent use of other anti-cancer agents or treatments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. | Through 3.5 years from study entry or until disease progression | * Overall response rate = CR + PR * Definitions per 2007 Cheson Lymphoma Response Criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | 30 days following the completion of treatment | * Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 * The higher the grade the worse the adverse event was considered |
| Cytostatic Overall Response Rate | From 6 months through 3.5 years after study entry | * Cytostatic overall response rate = CR + PR + SD greater than or equal to 6 months * Definitions per 2007 Cheson Lymphoma Response Criteria |
| Participant Response Rate in Relapsed or Refractory cHL. | Through 3.5 years from study entry or until disease progression | -Definitions per 2007 Cheson Lymphoma Response Criteria |
| Time to Progression (TTP). | Through 3.5 years from study entry or until disease progression | -Time to progression (TTP) is defined as the time from study entry until documented lymphoma progression or death as a result of lymphoma. |
| Overall Survival (OS) | Through 3.5 years from study entry or until disease progression | Overall survival is defined as the time from entry onto the clinical trial until death as a result of any cause. |
| Relapse Free Survival (RFS) | Through 3.5 years from study entry or until disease progression | — |
| Event Free Survival (EFS). | Through 3.5 years from study entry or until disease progression | -Event-free survival (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death). |
| Duration of Response | Through 3.5 years from study entry or until disease progression | -Duration of response: defined as the interval from the date of response (CR or PR) is documented to the date of progression, taking as reference the smallest measurements recorded since the treatment started |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 * The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2
* Lenalidomide 25 mg per day PO daily on days 1-21 of a 28 day cycle. | 38 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 * The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2
* Lenalidomide 25 mg per day PO daily on days 1-28 of a 28 day cycle. | 42 |
| Total | 80 |
Baseline characteristics
| Characteristic | Cohort 1 - Lenalidomide Daily on Days 1-21 | Cohort 2 - Lenalidomide Daily on Days 1-28 | Total |
|---|---|---|---|
| Age, Continuous | 34 years | 38 years | 36 years |
| Region of Enrollment United States | 38 Participants | 42 Participants | 80 Participants |
| Sex: Female, Male Female | 22 Participants | 18 Participants | 40 Participants |
| Sex: Female, Male Male | 16 Participants | 24 Participants | 40 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 38 / 38 | 42 / 42 |
| serious Total, serious adverse events | 9 / 38 | 10 / 42 |
Outcome results
Primary
Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL.
* Overall response rate = CR + PR * Definitions per 2007 Cheson Lymphoma Response Criteria
Time frame: Through 3.5 years from study entry or until disease progression
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. | 21.0 percentage of participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. | 28.6 percentage of participants |
Secondary
Cytostatic Overall Response Rate
* Cytostatic overall response rate = CR + PR + SD greater than or equal to 6 months * Definitions per 2007 Cheson Lymphoma Response Criteria
Time frame: From 6 months through 3.5 years after study entry
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Cytostatic Overall Response Rate | 15 Participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Cytostatic Overall Response Rate | 18 Participants |
Secondary
Duration of Response
-Duration of response: defined as the interval from the date of response (CR or PR) is documented to the date of progression, taking as reference the smallest measurements recorded since the treatment started
Time frame: Through 3.5 years from study entry or until disease progression
Population: (2) participants were not evaluable in Cohort 2 because 2 patients did not have progression, death dates, or last follow-up dates so time to progression cannot be calculated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Duration of Response | 3.68 months |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Duration of Response | 4.08 months |
Secondary
Event Free Survival (EFS).
-Event-free survival (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death).
Time frame: Through 3.5 years from study entry or until disease progression
Population: 2 participants in Cohort 2 were not evaluable because these patients did not have a date of progression, treatment failure, death or last follow-up so RFS could not be calculated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Event Free Survival (EFS). | 3.78 months |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Event Free Survival (EFS). | 3.93 months |
Secondary
Overall Survival (OS)
Overall survival is defined as the time from entry onto the clinical trial until death as a result of any cause.
Time frame: Through 3.5 years from study entry or until disease progression
Population: 1 participant was not evaluable in Cohort 1 and 5 participants were not evaluable in Cohort 2 because these participants did not have death dates or last follow-up dates so overall survival cannot be calculated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Overall Survival (OS) | 17.434 months |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Overall Survival (OS) | 23.717 months |
Secondary
Participant Response Rate in Relapsed or Refractory cHL.
-Definitions per 2007 Cheson Lymphoma Response Criteria
Time frame: Through 3.5 years from study entry or until disease progression
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Participant Response Rate in Relapsed or Refractory cHL. | PR | 7 Participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Participant Response Rate in Relapsed or Refractory cHL. | PD | 14 Participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Participant Response Rate in Relapsed or Refractory cHL. | CR | 1 Participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Participant Response Rate in Relapsed or Refractory cHL. | Not evaluable | 3 Participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Participant Response Rate in Relapsed or Refractory cHL. | SD | 13 Participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Participant Response Rate in Relapsed or Refractory cHL. | Unknown | 0 Participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Participant Response Rate in Relapsed or Refractory cHL. | SD | 11 Participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Participant Response Rate in Relapsed or Refractory cHL. | CR | 3 Participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Participant Response Rate in Relapsed or Refractory cHL. | PR | 9 Participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Participant Response Rate in Relapsed or Refractory cHL. | Unknown | 1 Participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Participant Response Rate in Relapsed or Refractory cHL. | PD | 14 Participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Participant Response Rate in Relapsed or Refractory cHL. | Not evaluable | 4 Participants |
Secondary
Relapse Free Survival (RFS)
Time frame: Through 3.5 years from study entry or until disease progression
Population: 2 participants in Cohort 2 were not evaluable because these patients did not have a date of progression, treatment failure, death or last follow-up so RFS could not be calculated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Relapse Free Survival (RFS) | 3.78 months |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Relapse Free Survival (RFS) | 3.93 months |
Secondary
Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL.
* Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 * The higher the grade the worse the adverse event was considered
Time frame: 30 days following the completion of treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low sodium | 2 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Dehydration | 2 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low albumin | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Lymphopenia | 9 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low calcium | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Infection without neutropenia | 2 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | High calcium | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | AST | 3 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low phosphorus | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Infection with neutropenia | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Hearing loss | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Anemia | 10 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Thrombosis/embolism | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Edema | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Rash | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | ALT | 2 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Febrile neutropenia | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Dyspnea | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Pneumonia | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Thrombocytopenia | 7 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | High potassium | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Pleural effusion | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Hyperuricemia | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Bilirubin | 2 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Confusion | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Alkaline phosphatase | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Dizziness | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Leukopenia | 11 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Speech impairment | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Abdominal pain | 1 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Chest pain | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Sensory neuropathy | 2 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Extremity pain | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low potassium | 3 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Muscle pain | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Fatigue | 3 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Secondary malignancy - MDS | 0 participants |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Neutropenia | 18 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Secondary malignancy - MDS | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Neutropenia | 20 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Leukopenia | 13 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Anemia | 4 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Lymphopenia | 10 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Thrombocytopenia | 8 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Fatigue | 2 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | AST | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | ALT | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Bilirubin | 2 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Sensory neuropathy | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Dehydration | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Infection without neutropenia | 3 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Infection with neutropenia | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Edema | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Dyspnea | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Pleural effusion | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Alkaline phosphatase | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Abdominal pain | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low potassium | 3 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low sodium | 2 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low albumin | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low calcium | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | High calcium | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Low phosphorus | 0 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Hearing loss | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Thrombosis/embolism | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Rash | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Febrile neutropenia | 2 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Pneumonia | 2 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | High potassium | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Hyperuricemia | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Confusion | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Dizziness | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Speech impairment | 2 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Chest pain | 1 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Extremity pain | 2 participants |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL. | Muscle pain | 1 participants |
Secondary
Time to Progression (TTP).
-Time to progression (TTP) is defined as the time from study entry until documented lymphoma progression or death as a result of lymphoma.
Time frame: Through 3.5 years from study entry or until disease progression
Population: (2) participants were not evaluable in Cohort 2 because 2 patients did not have progression, death dates, or last follow-up dates so time to progression cannot be calculated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | Time to Progression (TTP). | 3.68 months |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | Time to Progression (TTP). | 4.08 months |